Adenosine transporter Inhibitors
1 drugsAbout Adenosine transporter
Adenosine transporters regulate extracellular adenosine concentration, modulating adenosine signaling by controlling cellular uptake and release. These membrane proteins, also known as nucleoside transporters, influence diverse physiological processes.
Currently, there is no genetic evidence directly linking adenosine transporters to specific diseases. However, modulating adenosine levels via these transporters holds therapeutic potential, particularly in the cardiovascular system.
Adenosine transporters are targeted by one FDA-approved drug, ASPIRIN AND DIPYRIDAMOLE, a small molecule used in cardiovascular medicine. This drug was first approved in 2009 and is marketed by AMNEAL PHARMS.
Top Adenosine transporter Drugs
AMNEAL PHARMS is the only company with an approved drug targeting adenosine transporters.
Low competition may indicate a niche market or high entry barriers; assess market potential before investing heavily.
Adenosine transporter Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Adenosine transporter, using small molecule modality.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies and potentially improve efficacy.
Adenosine transporter Clinical Trials 531 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Adenosine transporter. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 72 | 57 | 3 | 10 | 95% |
| Phase 2 | 107 | 68 | 17 | 21 | 80% |
| Phase 3 | 128 | 54 | 22 | 52 | 71% |
| Phase 4 | 224 | 125 | 29 | 70 | 81% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Adenosine transporter Drug Approval Timeline (2009 - 2009)
The first and only drug targeting adenosine transporters was approved in 2009.
The lack of recent approvals suggests a saturated market or challenges in developing new therapies; investigate reasons for stagnation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 328 (49 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Adenosine transporter. A trial counts if an approved drug acting on Adenosine transporter is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.